Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
The new facility marks a significant milestone for Fredun Pharmaceuticals as it expands its footprint in the rapidly growing pet care industry in India
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%
Total Income in Q2 FY25 stood at Rs. 532.18 crore
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Subscribe To Our Newsletter & Stay Updated
